Abstract

A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is preferably free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1- difluoroethane (R-152a); (b) a surfactant component that comprises at least one surfactant compound other than oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

IPC Classes  ?

• A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
• A61K 9/12 - Aerosols; Foams
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

Abstract

A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R- 152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 11/06 - Antiasthmatics

Abstract

A surfactant-free pharmaceutical composition is described. The composition consists essentially of: (a) a drug component consisting of salbutamol sulphate; and (b) a propellant component consisting essentially of 1,1-difluoroethane (R-152a). A method for preparing the pharmaceutical composition is also described. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 11/06 - Antiasthmatics

Abstract

A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1 -difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

IPC Classes  ?

• A61K 9/12 - Aerosols; Foams

Abstract

A method for preparing a ternary or higher zeotropic refrigerant mixture comprising components of different volatilities is described. The method comprises: mixing together the less volatile components of the mixture in a pre-blending process; and separately adding the most volatile component to the pre-blended mixture by pressure or mass flow control so that the desired initial liquid composition is attained. The liquid zeotropic refrigerant mixture that is prepared may be transferred from a container in which it is held to another container or to a piece of equipment that is to use the refrigerant mixture. This method comprises the steps of: removing at least a portion of the prepared liquid zeotropic refrigerant mixture from a container in which it is held; charging the liquid zeotropic refrigerant mixture that is removed to another container or to a piece of equipment in which it is to be used; and adding at least the most volatile component of the refrigerant mixture to the holding container to compensate for the removal of liquid refrigerant mixture therefrom.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

A process for treating a composition comprising one or more desired (hydro)halocarbons and one or more undesired sulphur containing impurities so as to reduce the concentration of at least one undesired sulphur containing impurity, the process comprising contacting the composition with an adsorbent comprising an acid stable molecular sieve having a pore size of from 2 to l0.ANG. and/or an activated carbon.

IPC Classes  ?

• C07C 17/389 - Separation; Purification; Stabilisation; Use of additives by adsorption on solids
• B01J 29/00 - Catalysts comprising molecular sieves
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine